In the study conducted by Fang et al., it was first revealed that emodin inhibits obesity by promoting M2 macrophage polarization through TREM2, and emodin is considered to be a clinical and translational candidate drug for preventing obesity and related metabolic diseases. The gene discussed is TREM2; the disease is obesity due to melanocortin 4 receptor deficiency.